{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:02:26Z","timestamp":1790946146966,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome, and the current standard of care is the use of tyrosine kinase inhibitors (TKI). However, some patients will not achieve a molecular response and may progress to blast crisis, and the underlying mechanisms remain to be clarified. In this study, next-generation sequencing was used to explore endogenous miRNAs in CML patients versus healthy volunteers, and miR-342-5p was identified as the primary target. We found that miR-342-5p was downregulated in CML patients and had a significant inhibitory effect on cell proliferation in CML. Through a luciferase reporter system, miR-342-5p was reported to target the 3\u2019-UTR domain of CCND1 and downregulated its expression. Furthermore, overexpression of miR-342-5p enhanced imatinib-induced DNA double-strand breaks and apoptosis. Finally, by analyzing clinical databases, we further confirmed that miR-342-5p was associated with predicted molecular responses in CML patients. In conclusion, we found that both in vivo and in vitro experiments and database cohorts showed that miR-342-5p plays a key role in CML patients, indicating that miR-342-5p may be a potential target for future CML treatment or prognostic evaluation.<\/jats:p>","DOI":"10.1038\/s41419-021-04209-2","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T15:59:26Z","timestamp":1633449566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance"],"prefix":"10.1038","volume":"12","author":[{"given":"Yi-Ying","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Fan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Guang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Hua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ying","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiue-Wei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeu-Chin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Nung","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Liang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-6924","authenticated-orcid":false,"given":"Yi-Lin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"4209_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91:252\u201365.","journal-title":"Am J Hematol"},{"key":"4209_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000140633","volume":"119","author":"JM Goldman","year":"2008","unstructured":"Goldman JM, Melo JV. BCR-ABL in chronic myelogenous leukemia-how does it work? Acta Haematol. 2008;119:212\u20137.","journal-title":"Acta Haematol"},{"key":"4209_CR3","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Ilaria Jr.","year":"1996","unstructured":"Ilaria RL Jr., Van Etten RA. P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31704\u201310.","journal-title":"J Biol Chem"},{"key":"4209_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561\u20136.","journal-title":"Nat Med"},{"key":"4209_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrg1990","volume":"8","author":"K Chen","year":"2007","unstructured":"Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8:93\u2013103.","journal-title":"Nat Rev Genet"},{"key":"4209_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2172-15-14","volume":"15","author":"S Montagner","year":"2014","unstructured":"Montagner S, Deho L, Monticelli S. MicroRNAs in hematopoietic development. BMC Immunol. 2014;15:14.","journal-title":"BMC Immunol"},{"key":"4209_CR7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.exphem.2007.08.021","volume":"35","author":"H Bruchova","year":"2007","unstructured":"Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol. 2007;35:1657\u201367.","journal-title":"Exp Hematol"},{"key":"4209_CR8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.2174\/138920291605150710122815","volume":"16","author":"M Ciccone","year":"2015","unstructured":"Ciccone M, Calin GA. MicroRNAs in myeloid hematological malignancies. Curr Genomics. 2015;16:336\u201348.","journal-title":"Curr Genomics"},{"key":"4209_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1182\/blood-2010-09-191312","volume":"117","author":"G Marcucci","year":"2011","unstructured":"Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011;117:1121\u20139.","journal-title":"Blood."},{"key":"4209_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3892\/mmr.2015.4502","volume":"13","author":"K Wang","year":"2016","unstructured":"Wang K, Xu Z, Wang N, Tian Y, Sun X, Ma Y. Analysis of microRNA and gene networks in human chronic myelogenous leukemia. Mol Med Rep. 2016;13:453\u201360.","journal-title":"Mol Med Rep."},{"key":"4209_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fonc.2017.00101","volume":"7","author":"J Dooley","year":"2017","unstructured":"Dooley J, Lagou V, Pasciuto E, Linterman MA, Prosser HM, Himmelreich U, et al. No Functional Role for microRNA-342 in a mouse model of pancreatic acinar carcinoma. Front Oncol. 2017;7:101.","journal-title":"Front Oncol"},{"key":"4209_CR12","doi-asserted-by":"crossref","unstructured":"Tseng CH, Huang WT, Chew CH, Lai JK, Tu SH, Wei PL, et al. Electrospun Polylactic Acid (PLLA) Microtube Array Membrane (MTAM)-an advanced substrate for anticancer drug screening. Materials. 2019;12:569.","DOI":"10.3390\/ma12040569"},{"key":"4209_CR13","doi-asserted-by":"crossref","unstructured":"Chew CH, Lee CW, Huang WT, Cheng LW, Chen A, Cheng TM, et al. Microtube array membrane (MTAM)-based encapsulated cell therapy for cancer treatment. Membranes. 2020;10:80.","DOI":"10.3390\/membranes10050080"},{"key":"4209_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68835-0","volume":"10","author":"H-C Su","year":"2020","unstructured":"Su H-C, Wu S-C, Yen L-C, Chiao L-K, Wang J-K, Chiu Y-L, et al. Gene expression profiling identifies the role of Zac1 in cervical cancer metastasis. Sci Rep. 2020;10:11837.","journal-title":"Sci Rep"},{"key":"4209_CR15","unstructured":"Lab WaP. Soft Agar Assay for Colony Formation [Available from: https:\/\/artscimedia.case.edu\/wp-content\/uploads\/sites\/198\/2016\/10\/31152714\/Soft_Agar_Assay_Protocol.pdf."},{"key":"4209_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","volume":"25","author":"G Bindea","year":"2009","unstructured":"Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091\u20133.","journal-title":"Bioinformatics."},{"key":"4209_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. the gene ontology consortium. Nat Genet. 2000;25:25\u20139.","journal-title":"Nat Genet"},{"key":"4209_CR18","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4209_CR19","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.12688\/f1000research.9090.1","volume":"5","author":"M Kucera","year":"2016","unstructured":"Kucera M, Isserlin R, Arkhangorodsky A, Bader GD. AutoAnnotate: a cytoscape app for summarizing networks with semantic annotations. F1000Res. 2016;5:1717.","journal-title":"F1000Res"},{"key":"4209_CR20","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/bioinformatics\/btm254","volume":"23","author":"S Davis","year":"2007","unstructured":"Davis S, Meltzer PS. GEOquery: a bridge between the gene expression omnibus (geo) and bioconductor. Bioinformatics. 2007;23:1846\u20137.","journal-title":"Bioinformatics."},{"key":"4209_CR21","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1182\/bloodadvances.2019000195","volume":"3","author":"CH Kok","year":"2019","unstructured":"Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, et al. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Adv. 2019;3:1610\u201321.","journal-title":"Blood Adv"},{"key":"4209_CR22","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006;103:2794\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4209_CR23","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1182\/blood-2009-09-241943","volume":"115","author":"A K\u00fchnl","year":"2010","unstructured":"K\u00fchnl A, G\u00f6kbuget N, Stroux A, Burmeister T, Neumann M, Heesch S, et al. High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood. 2010;115:3737\u201344.","journal-title":"Blood."},{"key":"4209_CR24","doi-asserted-by":"crossref","unstructured":"Schmitz U, Shah JS, Dhungel BP, Monteuuis G, Luu PL, Petrova V, et al. Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients. Cancers. 2020;12:3738.","DOI":"10.3390\/cancers12123738"},{"key":"4209_CR25","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med. 2017;23:692\u2013702.","journal-title":"Nat Med"},{"key":"4209_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 2013;14:7.","journal-title":"BMC Bioinforma"},{"key":"4209_CR27","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1080\/21691401.2019.1596930","volume":"47","author":"H Wang","year":"2019","unstructured":"Wang H, He H, Yang C. miR-342 suppresses the proliferation and invasion of acute myeloid leukemia by targeting Naa10p. Artif Cells Nanomed Biotechnol. 2019;47:3671\u20136.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"4209_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jhep.2020.07.039","volume":"74","author":"RM Komoll","year":"2021","unstructured":"Komoll RM, Hu Q, Olarewaju O, von Dohlen L, Yuan Q, Xie Y, et al. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. J Hepatol. 2021;74:122\u201334.","journal-title":"J Hepatol"},{"key":"4209_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.omtn.2019.04.017","volume":"16","author":"FQ Dai","year":"2019","unstructured":"Dai FQ, Li CR, Fan XQ, Tan L, Wang RT, Jin H. miR-150-5p inhibits non-small-cell lung cancer metastasis and recurrence by targeting HMGA2 and beta-Catenin signaling. Mol Ther Nucleic Acids. 2019;16:675\u201385.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4209_CR30","doi-asserted-by":"publisher","first-page":"e0168171","DOI":"10.1371\/journal.pone.0168171","volume":"11","author":"TC Yeh","year":"2016","unstructured":"Yeh TC, Huang TT, Yeh TS, Chen YR, Hsu KW, Yin PH, et al. miR-151-3p Targets TWIST1 to repress migration of human breast cancer cells. PLoS One. 2016;11:e0168171.","journal-title":"PLoS One"},{"key":"4209_CR31","first-page":"7376","volume":"11","author":"C Liu","year":"2019","unstructured":"Liu C, Li W, Zhang L, Song C, Yu H. Tumor-suppressor microRNA-151-5p regulates the growth, migration and invasion of human breast cancer cells by inhibiting SCOS5. Am J Transl Res. 2019;11:7376\u201384.","journal-title":"Am J Transl Res"},{"key":"4209_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13046-017-0532-2","volume":"36","author":"Q Li","year":"2017","unstructured":"Li Q, Li Z, Wei S, Wang W, Chen Z, Zhang L, et al. Overexpression of miR-584-5p inhibits proliferation and induces apoptosis by targeting WW domain-containing E3 ubiquitin protein ligase 1 in gastric cancer. J Exp Clin Cancer Res. 2017;36:59.","journal-title":"J Exp Clin Cancer Res"},{"key":"4209_CR33","first-page":"475","volume":"18","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Sui R, Chen Y, Liang H, Shi J, Piao H. Downregulation of miR-485-3p promotes glioblastoma cell proliferation and migration via targeting RNF135. Exp Ther Med. 2019;18:475\u201382.","journal-title":"Exp Ther Med"},{"key":"4209_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0950-x","volume":"9","author":"S Chen","year":"2018","unstructured":"Chen S, Wu J, Jiao K, Wu Q, Ma J, Chen D, et al. MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78\/mTOR axis in gastric cancer. Cell Death Dis. 2018;9:1070.","journal-title":"Cell Death Dis"},{"key":"4209_CR35","doi-asserted-by":"publisher","first-page":"e35501","DOI":"10.1371\/journal.pone.0035501","volume":"7","author":"OH Rokah","year":"2012","unstructured":"Rokah OH, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One. 2012;7:e35501.","journal-title":"PLoS One"},{"key":"4209_CR36","doi-asserted-by":"publisher","first-page":"e75815","DOI":"10.1371\/journal.pone.0075815","volume":"8","author":"VA Morris","year":"2013","unstructured":"Morris VA, Zhang A, Yang T, Stirewalt DL, Ramamurthy R, Meshinchi S, et al. MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitors. PLoS One. 2013;8:e75815.","journal-title":"PLoS One"},{"key":"4209_CR37","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1182\/blood-2014-11-612507","volume":"125","author":"MF Alemdehy","year":"2015","unstructured":"Alemdehy MF, Haanstra JR, de Looper HW, van Strien PM, Verhagen-Oldenampsen J, Caljouw Y, et al. ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation. Blood. 2015;125:3937\u201348.","journal-title":"Blood."},{"key":"4209_CR38","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-16-2936","volume":"23","author":"MK Sannigrahi","year":"2017","unstructured":"Sannigrahi MK, Sharma R, Singh V, Panda NK, Rattan V, Khullar M. Role of Host miRNA Hsa-miR-139-3p in HPV-16-Induced Carcinomas. Clin Cancer Res. 2017;23:3884\u201395.","journal-title":"Clin Cancer Res"},{"key":"4209_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood.2019002045","volume":"135","author":"YL Su","year":"2020","unstructured":"Su YL, Wang X, Mann M, Adamus TP, Wang D, Moreira DF, et al. Myeloid cell-targeted miR-146a mimic inhibits NF-kappaB-driven inflammation and leukemia progression in vivo. Blood. 2020;135:167\u201380.","journal-title":"Blood."},{"key":"4209_CR40","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.7150\/jca.34972","volume":"10","author":"H Wu","year":"2019","unstructured":"Wu H, Yin J, Ai Z, Li G, Li Y, Chen L. Overexpression of miR-4433 by suberoylanilide hydroxamic acid suppresses growth of CML cells and induces apoptosis through targeting Bcr-Abl. J Cancer. 2019;10:5671\u201380.","journal-title":"J Cancer"},{"key":"4209_CR41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3904\/kjim.2017.102","volume":"34","author":"YG Lee","year":"2019","unstructured":"Lee YG, Kim I, Oh S, Shin DY, Koh Y, Lee KW. Small RNA sequencing profiles of mir-181 and mir-221, the most relevant microRNAs in acute myeloid leukemia. Korean J Intern Med. 2019;34:178\u201383.","journal-title":"Korean J Intern Med"},{"key":"4209_CR42","first-page":"4177","volume":"130","author":"SH Han","year":"2017","unstructured":"Han SH, Kim S-H, Hyoung-June K, Yoonsung L, Choi S-Y, Gyeongsin P, et al. Mir-424 and Mir-503 regulates Cobll1 expression during the CML progression. Blood. 2017;130:4177.","journal-title":"Blood."},{"key":"4209_CR43","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1182\/blood-2006-06-032490","volume":"109","author":"H Modi","year":"2007","unstructured":"Modi H, McDonald T, Chu S, Yee JK, Forman SJ, Bhatia R. Role of BCR\/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood. 2007;109:5411\u201321.","journal-title":"Blood."},{"key":"4209_CR44","doi-asserted-by":"crossref","unstructured":"Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.","DOI":"10.7554\/eLife.05005"},{"key":"4209_CR45","doi-asserted-by":"publisher","first-page":"D163","DOI":"10.1093\/nar\/gkq1107","volume":"39","author":"SD Hsu","year":"2011","unstructured":"Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011;39:D163\u20139.","journal-title":"Nucleic Acids Res"},{"key":"4209_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2003-5-1-r1","volume":"5","author":"AJ Enright","year":"2003","unstructured":"Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in Drosophila. Genome Biol. 2003;5:R1.","journal-title":"Genome Biol"},{"key":"4209_CR47","doi-asserted-by":"publisher","first-page":"e13984","DOI":"10.1371\/journal.pone.0013984","volume":"5","author":"D Merico","year":"2010","unstructured":"Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5:e13984.","journal-title":"PLoS One"},{"key":"4209_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/2211536608666181206124922","volume":"8","author":"EM Lindholm","year":"2019","unstructured":"Lindholm EM, Leivonen SK, Undlien E, Nebdal D, Git A, Caldas C, et al. miR-342-5p as a potential regulator of HER2 breast cancer cell growth. Microrna. 2019;8:155\u201365.","journal-title":"Microrna"},{"key":"4209_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-317","volume":"9","author":"DM Cittelly","year":"2010","unstructured":"Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 2010;9:317.","journal-title":"Mol Cancer"},{"key":"4209_CR50","doi-asserted-by":"publisher","first-page":"99978","DOI":"10.18632\/oncotarget.21577","volume":"8","author":"J Young","year":"2017","unstructured":"Young J, Kawaguchi T, Yan L, Qi Q, Liu S, Takabe K. Tamoxifen sensitivity-related microRNA-342 is a useful biomarker for breast cancer survival. Oncotarget 2017;8:99978\u201389.","journal-title":"Oncotarget"},{"key":"4209_CR51","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113:1619\u201330.","journal-title":"Blood."},{"key":"4209_CR52","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1365-2141.2008.07221.x","volume":"142","author":"ES Jose-Eneriz","year":"2008","unstructured":"Jose-Eneriz ES, Roman-Gomez J, Cordeu L, Ballestar E, Garate L, Andreu EJ, et al. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia. Br J Haematol. 2008;142:571\u201382.","journal-title":"Br J Haematol"},{"key":"4209_CR53","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1080\/10428190400003317","volume":"45","author":"JH Liu","year":"2004","unstructured":"Liu JH, Yen CC, Lin YC, Gau JP, Yang MH, Chao TC, et al. Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia. Leuk Lymphoma. 2004;45:2419\u201325.","journal-title":"Leuk Lymphoma"},{"key":"4209_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0407-0","volume":"14","author":"N Sharma","year":"2015","unstructured":"Sharma N, Magistroni V, Piazza R, Citterio S, Mezzatesta C, Khandelwal P, et al. BCR\/ABL1 and BCR are under the transcriptional control of the MYC oncogene. Mol Cancer. 2015;14:132.","journal-title":"Mol Cancer"},{"key":"4209_CR55","first-page":"1854","volume":"11","author":"NP Shah","year":"1991","unstructured":"Shah NP, Witte ON, Denny CT. Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines. Mol Cell Biol. 1991;11:1854\u201360.","journal-title":"Mol Cell Biol"},{"key":"4209_CR56","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/leu.2010.101","volume":"24","author":"M Marega","year":"2010","unstructured":"Marega M, Piazza RG, Pirola A, Redaelli S, Mogavero A, Iacobucci I, et al. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase\/blast crisis CML patients. Leukemia. 2010;24:1445\u20139.","journal-title":"Leukemia."},{"key":"4209_CR57","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/1541-7786.MCR-10-0040","volume":"8","author":"J Kuroda","year":"2010","unstructured":"Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, et al. Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res. 2010;8:994\u20131001.","journal-title":"Mol Cancer Res"},{"key":"4209_CR58","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.dnarep.2013.04.022","volume":"12","author":"M Takagi","year":"2013","unstructured":"Takagi M, Sato M, Piao J, Miyamoto S, Isoda T, Kitagawa M, et al. ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia. DNA Repair. 2013;12:500\u20137.","journal-title":"DNA Repair"},{"key":"4209_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/ncb1337","volume":"8","author":"A Jazayeri","year":"2006","unstructured":"Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol. 2006;8:37\u201345.","journal-title":"Nat Cell Biol"},{"key":"4209_CR60","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2009.01.024","volume":"33","author":"B Shiotani","year":"2009","unstructured":"Shiotani B, Zou L. Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks. Mol Cell. 2009;33:547\u201358.","journal-title":"Mol Cell"},{"key":"4209_CR61","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.dnarep.2013.10.004","volume":"12","author":"J Saha","year":"2013","unstructured":"Saha J, Wang M, Cucinotta FA. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation. DNA Repair. 2013;12:1143\u201351.","journal-title":"DNA Repair"},{"key":"4209_CR62","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/cbin.10460","volume":"39","author":"M Morii","year":"2015","unstructured":"Morii M, Fukumoto Y, Kubota S, Yamaguchi N, Nakayama Y, Yamaguchi N. Imatinib inhibits inactivation of the ATM\/ATR signaling pathway and recovery from adriamycin\/doxorubicin-induced DNA damage checkpoint arrest. Cell Biol Int. 2015;39:923\u201332.","journal-title":"Cell Biol Int"},{"key":"4209_CR63","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1158\/0008-5472.CAN-09-0548","volume":"69","author":"I Skorta","year":"2009","unstructured":"Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE, van der Kuip H. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. Cancer Res. 2009;69:9337\u201345.","journal-title":"Cancer Res"},{"key":"4209_CR64","doi-asserted-by":"publisher","first-page":"5197","DOI":"10.1182\/blood.V124.21.5197.5197","volume":"124","author":"S Mohanty","year":"2014","unstructured":"Mohanty S, Tran T, Sandoval N, Mohanty A, Bedell V, Wu J, et al. Cyclin D1 promotes survival and chemoresistance by maintaining ATR and CHEK1 signaling in TP53-deficient mantle cell lymphoma cell lines. Blood. 2014;124:5197. -","journal-title":"Blood."},{"key":"4209_CR65","doi-asserted-by":"publisher","first-page":"994","DOI":"10.4161\/cc.5.9.2722","volume":"5","author":"M Nieborowska-Skorska","year":"2006","unstructured":"Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A, et al. ATR-Chk1 axis protects BCR\/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle. 2006;5:994\u20131000.","journal-title":"Cell Cycle"},{"key":"4209_CR66","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/0145-2126(93)90161-D","volume":"17","author":"JC Law","year":"1993","unstructured":"Law JC, Ritke MK, Yalowich JC, Leder GH, Ferrell RE. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res. 1993;17:1045\u201350.","journal-title":"Leuk Res"},{"key":"4209_CR67","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0145-2126(01)00107-2","volume":"26","author":"DS Fleckenstein","year":"2002","unstructured":"Fleckenstein DS, Uphoff CC, Drexler HG, Quentmeier H. Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leuk Res. 2002;26:207\u201314.","journal-title":"Leuk Res"},{"key":"4209_CR68","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/sj.leu.2402486","volume":"16","author":"A Janowska-Wieczorek","year":"2002","unstructured":"Janowska-Wieczorek A, Majka M, Marquez-Curtis L, Wertheim JA, Turner AR, Ratajczak MZ. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia. 2002;16:1160\u20136.","journal-title":"Leukemia."},{"key":"4209_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03803-8","volume":"12","author":"Q He","year":"2021","unstructured":"He Q, Ye A, Ye W, Liao X, Qin G, Xu Y, et al. Cancer-secreted exosomal miR-21-5p induces angiogenesis and vascular permeability by targeting KRIT1. Cell Death Dis. 2021;12:576.","journal-title":"Cell Death Dis"},{"key":"4209_CR70","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/jso.23243","volume":"107","author":"HL Tsai","year":"2013","unstructured":"Tsai HL, Yeh YS, Chang YT, Yang IP, Lin CH, Kuo CH, et al. Co-existence of cyclin D1 and vascular endothelial growth factor protein expression is a poor prognostic factor for UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol. 2013;107:148\u201354.","journal-title":"J Surg Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04209-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04209-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04209-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:11:19Z","timestamp":1669972279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04209-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":70,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["4209"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-04209-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]},"assertion":[{"value":"6 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Tri-Service General Hospital, Taipei, Taiwan (1-105-05-052). All the in vivo experimental procedures were performed according to the standards approved by the Laboratory Animal Center in National Defense Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS STATEMENT"}}],"article-number":"908"}}